Ostovic D - Search Results

1

pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs.

Lin JH, Chen IW, Vastag KJ, Ostovic D. Lin JH, et al. Among authors: ostovic d. Drug Metab Dispos. 1995 Jul;23(7):730-5. Drug Metab Dispos. 1995. PMID: 7587962

2

Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs.

Kwei GY, Novak LB, Hettrick LA, Reiss ER, Ostovic D, Loper AE, Lui CY, Higgins RJ, Chen IW, Lin JH. Kwei GY, et al. Among authors: ostovic d. Pharm Res. 1995 Jun;12(6):884-8. doi: 10.1023/a:1016269206048. Pharm Res. 1995. PMID: 7667195

3

The integration of medicinal chemistry, drug metabolism, and pharmaceutical research and development in drug discovery and development. The story of Crixivan, an HIV protease inhibitor.

Lin JH, Ostovic D, Vacca JP. Lin JH, et al. Among authors: ostovic d. Pharm Biotechnol. 1998;11:233-55. doi: 10.1007/0-306-47384-4_11. Pharm Biotechnol. 1998. PMID: 9760683 Review. No abstract available.

4

A rapid bioassay for the determination of non-nucleoside HIV-1 reverse transcriptase inhibitor plasma levels.

O'Brien JA, Ostovic D, Schorn TW, Smith SJ, Ruffing TL, Siegl PK, Goldman ME. O'Brien JA, et al. Among authors: ostovic d. Life Sci. 1993;52(3):243-9. doi: 10.1016/0024-3205(93)90215-o. Life Sci. 1993. PMID: 7678687

5

Formation of a chromophoric complex between alendronate and copper(II) ions.

Ostović D, Stelmach C, Hulshizer B. Ostović D, et al. Pharm Res. 1993 Mar;10(3):470-2. doi: 10.1023/a:1018969112754. Pharm Res. 1993. PMID: 8464827 No abstract available.

6

Design and characterization of a surfactant-enriched tablet formulation for oral delivery of a poorly water-soluble immunosuppressive agent.

Ruddy SB, Matuszewska BK, Grim YA, Ostovic D, Storey DE. Ruddy SB, et al. Among authors: ostovic d. Int J Pharm. 1999 May 25;182(2):173-86. doi: 10.1016/s0378-5173(99)00056-3. Int J Pharm. 1999. PMID: 10341307

7

Assessing aggregation of peptide conjugate of doxorubicin using quasi-elastic light scattering and 600 MHz NMR.

Karki SB, Ostovic D. Karki SB, et al. Among authors: ostovic d. Int J Pharm. 2004 Mar 1;271(1-2):181-7. doi: 10.1016/j.ijpharm.2003.11.002. Int J Pharm. 2004. PMID: 15129984

8

Design of an i.v. formulation of an unstable prodrug candidate for prostate cancer treatment: solution chemistry of N-(glutaryl-hyp-ala-ser-cyclohexylglycyl-gln-ser-leu)-doxorubicin.

Karki SB, Treemaneekarn V, Ostovic D, Nerurkar M, Almarsson O. Karki SB, et al. Among authors: ostovic d. Drug Dev Ind Pharm. 2006 Mar;32(3):327-34. doi: 10.1080/03639040500518997. Drug Dev Ind Pharm. 2006. PMID: 16556537

9

Identification of oxidative degradates of the thrombin inhibitor, 3-(2-phenethylamino)-6-methyl-1-(2-amino-6-methyl-5-methyleneca rboxamidomethylpyridinyl)pyrazinone, using liquid chromatography/mass spectrometry and liquid chromatography/tandem mass spectrometry.

Wu Y, Chen X, Gier L, Almarsson O, Ostovic D, Loper AE. Wu Y, et al. Among authors: ostovic d. J Pharm Biomed Anal. 1999 Jul;20(3):471-85. doi: 10.1016/s0731-7085(99)00035-7. J Pharm Biomed Anal. 1999. PMID: 10701963

10

A quantitative kinetic study of polysorbate autoxidation: the role of unsaturated fatty acid ester substituents.

Yao J, Dokuru DK, Noestheden M, Park SS, Kerwin BA, Jona J, Ostovic D, Reid DL. Yao J, et al. Among authors: ostovic d. Pharm Res. 2009 Oct;26(10):2303-13. doi: 10.1007/s11095-009-9946-7. Epub 2009 Aug 8. Pharm Res. 2009. PMID: 19669100

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

13 results

Search Page

Filters